Eli Lil­ly shep­herds its $1.1B con­tender through an­oth­er PhI­II chal­lenge on the way to the FDA

4 years ago
R&D

Third Rock­'s Am­bys clos­es a megaround with the clin­ic still a ways off for its re­gen­er­a­tive cells for liv­er dis­ease

4 years ago
Financing

FDA clears first long-act­ing HIV-pre­ven­tion in­jectable, giv­ing Vi­iV claim to his­toric OK

4 years ago
FDA+

Aldeyra shares spi­ral af­ter a late-stage fail­ure in dry eye dis­ease — but that won't stop its pur­suit of an NDA

4 years ago
R&D
FDA+

DOJ charges for­mer Five Prime tri­al­ist with se­cu­ri­ties fraud af­ter $134K in in­sid­er trad­ing prof­its

4 years ago
People
Pharma

One of Pfiz­er’s Duchenne gene ther­a­py tri­als put on hold in wake of pa­tient death as high-dose AAV con­cerns still ...

4 years ago
R&D
Cell/Gene Tx

Pi­o­neer­ing chemist and Cal­tech pro­fes­sor Robert Grubbs pass­es away at 79 years old

4 years ago
People

Pounc­ing on next-gen I/O play, Sanofi ac­quires Amu­nix for $1B+ and picks up 'u­ni­ver­sal mask' tech

4 years ago
Deals

EQRx wants to turn drug pric­ing re­form on its head. Can it suc­ceed, or will Big Phar­ma stop it in its tracks?

4 years ago
Pharma
In Focus

‘The pur­suit of nor­mal': Pfiz­er launch­es first Covid-19 vac­cine TV ads

4 years ago
Pharma
Marketing

Ab­b­Vie pe­ti­tions trade com­mis­sion to ban Alvotech's Hu­mi­ra biosim­i­lar; Cy­to­ki­net­ics li­cens­es heart drug to Chi­nese ...

4 years ago
News Briefing

Covid-19 roundup: No­vavax fi­nal­ly re­ceives the go-ahead in Eu­rope for its vac­cine; CDC strug­gles to track Omi­cron

4 years ago
Coronavirus

Mer­ck KGaA snatch­es up Gene­va biotech as re­pur­posed chemother­a­py mis­sion strikes a 'Chord'

4 years ago
Deals

We­govy woes con­tin­ue as man­u­fac­tur­ing is­sues will lead to fur­ther short­age of Novo's obe­si­ty drug

4 years ago
Manufacturing

Tim Lu takes Sen­ti and its gene cir­cuit tech pub­lic in $296M deal rid­ing on Omid Farokhzad's SPAC

4 years ago
Deals

Joe Manchin quash­es any im­me­di­ate hopes for ma­jor drug pric­ing re­forms

4 years ago
Pharma

Blue­bird shares tank af­ter FDA puts an­oth­er hold on its long de­layed sick­le cell gene ther­a­py

4 years ago
R&D
FDA+

Weeks af­ter $143M megaround, low-pro­file Cin­Cor looks to vault on­to Nas­daq with a Roche castoff

4 years ago
Financing

Roche, Genen­tech tap re­gen­er­a­tive cell ther­a­py play­er for drug col­lab­o­ra­tion in eye dis­ease

4 years ago
R&D

Weeks af­ter earn­ing CEO's stamp of ap­proval, a No­var­tis skin drug los­es head-to-head bat­tle with stan­dard of care

4 years ago
R&D
Pharma

FDA hands As­traZeneca-Am­gen broad ap­proval for asth­ma an­ti­body, clear­ing block­buster path

4 years ago
R&D
Pharma

No­var­tis turns to BeiGene again for the next big check­point tar­get, pay­ing $300M to jump in­to TIG­IT race

4 years ago
Deals
China

Bio­gen slash­es Aduhelm price in half, fore­shad­ows sig­nif­i­cant lay­offs as sales con­tin­ue to stag­nate

4 years ago
Pharma

Ar­genx touts first-in-class win for a rare dis­ease that caus­es life-threat­en­ing mus­cle weak­ness

4 years ago
FDA+
First page Previous page 606607608609610611612 Next page Last page
A service from the Financial Times